GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » NonCurrent Deferred Liabilities

Healthwell Acquisition I (Healthwell Acquisition I) NonCurrent Deferred Liabilities : $0.45 Mil (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Healthwell Acquisition I NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Healthwell Acquisition I's non-current deferred liabilities for the quarter that ended in Jun. 2023 was $0.45 Mil.

Healthwell Acquisition I NonCurrent Deferred Liabilities Historical Data

The historical data trend for Healthwell Acquisition I's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Healthwell Acquisition I NonCurrent Deferred Liabilities Chart

Healthwell Acquisition I Annual Data
Trend Dec21 Dec22
NonCurrent Deferred Liabilities
- 0.37

Healthwell Acquisition I Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.20 0.37 0.40 0.45

Healthwell Acquisition I NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Healthwell Acquisition I's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Healthwell Acquisition I (Healthwell Acquisition I) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Healthwell Acquisition Corp I (NAS:HWELW) » Definitions » NonCurrent Deferred Liabilities
Comparable Companies
PWUP BLUA CBRG CHAA NNAG TGAA DPCS EGGF PORT CITE PBAJ SVMB SCRM CVII AAC GHIX ALCC AACT DWAC SAGA
Traded in Other Exchanges
N/A
Address
1001 Green Bay Road, Suite 227, Winnetka, IL, USA, 60093
Website
https://www.healthwellspac.com
Healthwell Acquisition Corp I is a blank check company.

Healthwell Acquisition I (Healthwell Acquisition I) Headlines

From GuruFocus

Healthwell Acquisition Corp. I Announces Termination of Business Combination with Starton Therapeutics, Inc.

By Business Wire • 11-04-2023

Starton Therapeutics Contracts Global Clinical Research Organization to Conduct STAR-LLD Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 07-10-2023

Starton Therapeutics Doses First Patient in Landmark STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire • 10-04-2023

Healthwell Acquisition Corp. I Announces Postponement of the Special Meeting of Stockholders to Approve the Proposed Business Combination with Starton Therapeutics, Inc. and Related Transactions

By Business Wire • 10-24-2023

Healthwell Acquisition Corp. I Announces Closing of $250,000,000 Initial Public Offering

By Business Wire Business Wire • 08-05-2021

Healthwell Acquisition Corp. I Announces Cancellation of Special Stockholder Meeting and its Intention to Liquidate

By Business Wire • 11-18-2023

Starton Therapeutics Announces the Opening of the First Clinical Site for STAR-LLD Lenalidomide Phase 1b Trial in Multiple Myeloma

By Business Wire • 09-13-2023

Starton Therapeutics Receives Authorization from the FDA to Proceed with STAR-LLD Lenalidomide Phase 1b Clinical Trial in Multiple Myeloma

By Business Wire Business Wire • 06-12-2023

Healthwell Acquisition Corp. I Announces the Separate Trading of Its Class A Common Stock and Warrants Commencing September 23, 2021

By Business Wire Business Wire • 09-22-2021

Starton Therapeutics Inc. and Healthwell Acquisition Corp. I to Combine and Create Publicly Traded Leader in Proprietary Continuous Delivery Technology for Cancer Treatments

By Business Wire Business Wire • 04-27-2023